<DOC>
	<DOCNO>NCT00257452</DOCNO>
	<brief_summary>To demonstrate tiotropium ( Spiriva® ) prolong QT interval ECG placebo</brief_summary>
	<brief_title>A Double-blind , Randomised Study Assess Influence Tiotropium ( Spiriva® )</brief_title>
	<detailed_description>The objective study demonstrate tiotropium prolong QT interval placebo . This achieve test non-inferiority hypothesis . Study Hypothesis : There one primary variable test non-inferiority : tiotropium high dose compare placebo : H0 : µ ( TIO,12 ) - µ ( PBO,12 ) &gt; = 10 m vs. H1 : µ ( TIO,12 ) - µ ( PBO,12 ) &lt; 10 m µ ( TIO,12 ) , µ ( PBO,12 ) represent mean change baseline QTcF 5 minute 2 hour 12 day treatment ( take mean time-matched difference baseline post-baseline value treatment period ) tiotropium 54 µg , placebo , respectively . If data suggest Fridericia correction poor study population , alternative correction explore ( QTcN ) . The correction formula would use replacement Fridericia correction would define unblinding data . Comparison ( ) : Placebo , moxifloxacin active control</detailed_description>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>All participant study healthy male female , range 21 50 year age body mass index ( BMI ) within 18.5 29.9 kg/m2 ( BMI calculation : weight kilogram divide square height meter ) . In accordance GCP local legislation volunteer give write informed consent prior admission study . Exclusion criterion : Any find medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24:00 hour ) within least one month less ten halflives respective drug enrolment study study Use drug might influence result trial 7 day prior enrolment study study Participation another trial investigational drug ( two month prior administration trial ) Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation ( &gt; 100 mL within four week prior administration trial ) Any laboratory value outside reference range indicative underlying disease poor health Excessive physical activity within last week trial trial Hypersensitivity tiotropium , moxifloxacin and/or relate drug class Heart rate screen &gt; 80 bpm &lt; 45 bpm Any screen ECG value outside reference range clinical relevance include , limited PR interval &gt; 220 m , QRS interval &gt; 115 m , QTcB QTcF &gt; 450 m , QT ( uncorrected ) &gt; 470 m For Female Subjects : Pregnancy Positive pregnancy test No adequate contraception ( adequate contraception e.g . sterilisation , IUP , oral contraceptive ) Inability maintain adequate contraception whole study period Lactation period .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>